Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

NCT04521140 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Corneal Edema
Corneal Defect
Corneal Transplant
Penetrating KeratoPlasty
Anterior Chamber Inflammation
Ocular Pain
Intraocular Pressure

Interventions

DRUG: Dextenza 0.4Mg Ophthalmic Insert
DRUG: Prednisolone Acetate 1% Oph Susp

Sponsor

Nicole Fram M.D.